Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart

Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart

<strong>Aims</strong> Emipagliflozin (EMPA) is a potent inhibitor of the renal sodium-glucose co-transporter 2 (SGLT2) and an effective treatment for type-2 diabetes. In patients with diabetes and heart failure, EMPA has cardioprotective effects independent of improved glycaemic control...

Full description

Bibliographic Details
Main Authors:	Chung, YJ, Park, KC, Tokar, S, Eykyn, TR, Fuller, W, Swietach, P, Pavlovic, D, Shattock, MJ
Format:	Journal article
Language:	English
Published:	European Society of Cardiology 2020

Similar Items

SGLT2 inhibitors and the cardiac Na+/H+ exchanger-1: the plot thickens
by: Chung, YJ, et al.
Published: (2021)

Empagliflozin inhibits Na+/H+ exchanger activity in human atrial cardiomyocytes
by: Maximilian Trum, et al.
Published: (2020-12-01)

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
by: Sanon VP, et al.
Published: (2017-05-01)

Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis
by: Cheng-Chih Chung, et al.
Published: (2023-02-01)

Sodium-glucose co-transporter-2 inhibitors in heart failure and chronic kidney disease: the role of empagliflozin
by: M. M. Batyushin
Published: (2021-04-01)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
by: Julie Kolwelter, et al.
Published: (2021-12-01)

Pushing and pulling the cardiac sodium/hydrogen exchanger.
by: Vaughan-Jones, R, et al.
Published: (2008)

Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Increases Antioxidative Capacity and Improves Renal Function in Diabetic Rats
by: Habib Yaribeygi, et al.
Published: (2023-06-01)

Highly selective sodium glucose cotransporter type 2 inhibitor empagliflozin neuroprotective potential in chronic brain dyscirculation
by: Оksana S. Fuks, et al.
Published: (2023-07-01)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
by: Dong-Dong Wang, et al.
Published: (2022-11-01)

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
by: Yi-Hsuan Lin, et al.
Published: (2019-11-01)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
by: Sjoukje van der Hoek, et al.
Published: (2023-04-01)

Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats
by: Kyung Ae Lee, et al.
Published: (2018-04-01)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
by: Victor Sokolov, et al.
Published: (2020-04-01)

Cardiomyocyte Na+/H+ exchanger-1 activity is reduced in hypoxia
by: Kandilci, H, et al.
Published: (2021)

Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice
by: Genlong Xue, et al.
Published: (2022-10-01)

The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
by: Hsiang-Chun Lee, et al.
Published: (2019-04-01)

Sodium–Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism
by: Yunke Tan, et al.
Published: (2021-10-01)

Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet
by: Vickers SP, et al.
Published: (2014-07-01)

The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms
by: Dilvin Semo, et al.
Published: (2023-02-01)

pH-Regulated Na(+) influx into the mammalian ventricular myocyte: the relative role of Na(+)-H(+) exchange and Na(+)-HCO Co-transport.
by: Vaughan-Jones, R, et al.
Published: (2006)

Intracellular sodium elevation reprograms cardiac metabolism
by: Dunja Aksentijević, et al.
Published: (2020-08-01)

Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure
by: Xuan Li, et al.
Published: (2021-03-01)

Acid-sensing ion channel blocker diminazene facilitates proton-induced excitation of afferent nerves in a similar manner that Na+/H+ exchanger blockers do
by: Yurii Tkachenko, et al.
Published: (2023-07-01)

The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
by: Matthias Oelze, et al.
Published: (2014-01-01)

Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys
by: Sungjin Chung, et al.
Published: (2019-03-01)

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
by: Qingmiao Shao, et al.
Published: (2019-11-01)

Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy
by: Changzhen Ren, et al.
Published: (2021-04-01)

Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes
by: Kwong-Man Ng, et al.
Published: (2018-10-01)

Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
by: Al-Anood Al-Shamasi, et al.
Published: (2021-11-01)

H+-extrusion by Na+-H+ exchange is localised at the surface sarcolemma in rat ventricular myocytes
by: Huc, LT, et al.
Published: (2007)

Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial
by: Kavitha Muthiah, et al.
Published: (2023-03-01)

Sarcolemmal localisation of Na+/H+ exchange and Na+-HCO3- co-transport influences the spatial regulation of intracellular pH in rat ventricular myocytes.
by: Garciarena, C, et al.
Published: (2013)

Empagliflozin in type 1 diabetes
by: Mathieu C, et al.
Published: (2019-08-01)

Empagliflozin and the Prevention of Heart Failure
by: Douglas L. Mann, MD, et al.
Published: (2017-08-01)

Computational Design of High-Affinity Blockers for Sodium Channel Na<sub>V</sub>1.2 from μ-Conotoxin KIIIA
by: Guangsi Meng, et al.
Published: (2022-02-01)

Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes
by: Lucia Scisciola, et al.
Published: (2023-09-01)

Docking Studies of Phthalimide Pharmacophore as a Sodium Channel Blocker
by: Maryam Iman, et al.
Published: (2013-09-01)

Temperature dependence of Na+-H+ exchange, Na+-HCO3- co-transport, intracellular buffering and intracellular pH in guinea-pig ventricular myocytes.
by: Ch'en, F, et al.
Published: (2003)

Cardiomyocyte Na+/H+ Exchanger-1 Activity Is Reduced in Hypoxia
by: Hilmi Burak Kandilci, et al.
Published: (2021-01-01)